Track the 케이엠제약 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are listed on the KR market, under the supervision of DART (FSS). Operating in the Banks sector, 케이엠제약 has published 56 public disclosures. Market capitalisation: €9.7bn. The latest transaction was reported on 8 July 2026 (Purchase). Among the most active insiders: 강일모. All data is free.
50
Insider Decl.
n/a
Thresholds
€109,057
36 ops.
Buy Volume
n/a
1 ops.
Sell Volume
30Σ signal
Buys €109,057n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,174 of 29,062 companies
12.5
score / 100
Value
6
Quality
19
FCF yld-27%
Earn yld-53%
EV/EBITDA·
ROE-13%
Gross mgn24%
Net mgn-25%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.